Trial Information

Health Related Quality of Life After Surgery and Oncological Treatment of Colorectal Liver Metastases A Prospective Multicenter Study

Background: Hepatic resection is the only treatment with potential curative intent for
patients having colorectal liver metastases. Combined with chemotherapy, the overall 5-year
survival is 40-50%. The disease free 5-year survival is about 20%, and about 70% of resected
patients experience recurrence from their disease. Even if surgery is superior all other
treatments, most patients will finally die from their cancer. However; surgery contributes
by adding years of life, and for a minority, a disease free life. There has been much effort
to study predictors for outcome after surgery, but little has been focused on quality of
life following this treatment.

Method: EORTC Validated questionnaire (European Organisation Research of Treatment of
Cancer) version QLQ-C30 (3.0) and QLQ LMC21. The patients fill out the questionnaire before
surgery as a baseline, and then after 3,6 and 12 months after surgery. The investigators
also register important clinicopathological data about each patient prospectively.